Trimeris.

PositionRegional Report: Triangle

DURHAM -- Trimeris, which is developing HIV drugs, asked the U.S. Securities and Exchange Commission for permission to sell 2 million additional shares of stock. Based on the price at the beginning of September, the offering could raise nearly $90...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT